Lexeo Therapeutics, Inc.

Lexeo Therapeutics (LXEO) has recorded zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating a clean operational surface in our recent ingestion window. However, low signal in a 90-day snapshot does not rule out structural risks—the company operates in a capital-intensive biotech sector where financing events and equity dilution patterns matter significantly. The full $49 Report extends analysis to 12 months of filings, maps dilution risk scores, contextualizes all 8-K activity, and surfaces AI-detected risk signals tied to cash burn and financing history. The full $49 Report adds these deeper structural and historical risk layers.